Member Info for travel_light

Link? Please

Affimers are not the same as antibodies.

Antibodies took time to be used in therapies. A long time.

Google it

Affimers are interesting and could be used in a similay way.

That they can be used in a test is not the same as a therapy “in principle”. They might be lethal, testing takes time.

A deal may well get done, but I would have thought it would involve funding different stages with milestone payments.

Why do you think that affimers are

A) better than antibodies currently under test
B) better than compounds blocking the same path
C) faster to bring to market given they have never been used in animals let alone humans.
D) better than plasma therapy

Bit of a negative view, but reasonable expectations still point to a great investment. Strong buy but not for the house built from one brick.

hi, not so sure about neutralising therapy. My understanding is it was done in a lab, against cells in a dish.

there are existing therapies which have been tested in humans, both compounds and antibodies involved in ACW2 pathway. Avacta would need to compete against those in the short term.

given affimers have not been tested in animals, let alone humans, the most that can be expected is the best candidates have been identified. Ensuring that affimers in any form would be safe for use long term in humans I would have thought would take some time. The affimer can bind to the virus, but I would have thought it means it can bind to whatever the virus is pretending to be.

strong buy on avacta but not due to its ability to be involved blocking the virus from entering cells. Neat and interesting yes, long term opportunity....possibly. Investment case.....hmmm antibodies look better bet in short term.

but i write SW, my medical knowledge is "take 2 aspirin".

what I like about the cancer treating aspects is Avacta has recently had two strings to their bow.

The pre-cision technology, which basically build on well proven existing treatments but adds value by lowering the systemic toxic effects.

The use of affirmers to expose tumour cells to the bodies own immune systems.

Time scales are long, and it's a buy and hold. If you don't have time to wait, look elsewhere. It's a pretty binary proposition (although 2 strings to bow). If either works, current valuation will change overnight.
The covid test, its short term, but then allows the development of multiple test for other conditions. This is where current valuation lies, and CEO has stated as such.

Whilst the latest grab for more money was a little unexpected, company now has a position where they can add lots of strings to the bow. They only need one hit.

To be honest I didn’t see anything wrong in that post.

Those risks are there. But in relation to the return I think avacta represents a good investment. No share is without risk. The timescales are unknown for lots of things. If you have a different opinion just say why you differ, cos throwing names means people stop reading and opinion remains unchallenged.

No need to throw stones cos someone says try and find balance.

Might be a case of give a dog a bad name.

Do companies get acquired often if they are in phase 1?

B2

PD-L1 inhibition would be for the treatment of various cancers not covid. AFAIK. Happy to be corrected. Affimers can be used across a range of targets, the c19 virus is only one.

The reason money not being poured inti neutralizing is that the affimer tech needs to be proven safe. Antibody route based on existing technology is probably low hanging fruit rather than affimer. Well proven and tested in a general sense. Long term thou it’s an obvious path to follow.

But that’s a very layman’s view. Others might know better.

Gmcc thanks

hopefully the robot has gone:-)

Beginners guide

https://youtu.be/UbFjiWOBErA

Bit more advanced (plus testing for cancer cells with high expression).

https://youtu.be/s2a_x1o5UEA

I guess each cancer needs it’s own trial?

Typing on a phone, this BB using 1990 tech, how hard to have a edit function open for 5 min after posting !!!!

Sorry about typos, phone types half the words.

https://www.grandviewresearch.com/press-release/global-monoclonal-antibodies-market

Quick google re affirmer usage instead of antibody and size of market.138 billion dollars market.

Affimer as far as I know have not been used in humans, so many a slip between fork and mouth. But if the price usable....wow.

What I am wondering is if an antibody is used to bind to a molecule to treat a disease and is protected by IPR, can an affimer come in and replace it without being subject to that IPR. You would think
that half the battle is knowing which molecules to bind to for what condition.

If affimers has no restriction then I guess avacta could cherry pick the treatments they target, rather than wait fir IPR to expire (as with the pre-cision tech).

Be grateful if someone who knows could post.

I guess if you want to discuss avacta ava004 treatment pls start a new thread. Robot killed this one:-)

Richken,

It’s a robot. Programmed to monitor the board. If a price is mentioned more than x it will post a randomly selected message about ramping. It then posts an alternative view and back and for. The declines. It’s like autoimmune disease for bb.

I might be wrong but it’s Sunday, it’s raining.

Read how the initial price was mentioned. Not exactly ramping but the script didn’t understand the context. Find another thread and test it.

People is basements being paid is so last century.

No where did I put my tin hat, PL have you a spare?

Interesting. 3 quid mentioned in conjunction with immortality (humour difficult for AI). In a thread about what avacta is actually delivering, hopefully somewhat informative.

Accusation of ramping

A defense why 3 quid is not ramping.

Thread goes of course and driven my sentiment and emotion. Information

Dummies guide to scripting needs updating.

I have seen some poor chat AI in my time...

I am pretty sure that if avacta found the secret to immortality, 2 quid would be easy. Does anyone know if Avacta is working with Hebe?

Scarabbeatle

No worries, my text is complicated:-)

Pl if avacta did I reckon it could get to 3 quid easily :-)

Also cells can die in a number of different ways. Being destroyed by T-cells is one.

There are also some cell lines that are “immortal”

https://en.m.wikipedia.org/wiki/Immortalised_cell_line

Goto admit I had the 100 million number in my head as test sold...?? back on the rails.

Feel a little stupid. Nobel prize stuff.

Antibodies are made from cell lines, not directly from animals(I think).

But the more I read the size of market becomes apparent. Stability of the final product an issue, and I think I saw somewhere that affimers are more stable.

Antibody treatment was nearest I could find and I think is a similar treatment to that being proposed with affimers (004). Involved in the OD-L1 (programmed cell death ligand ).

https://en.m.wikipedia.org/wiki/Nivolumab